You are here: Home / Services and Specialities / Leadership Sinai Centre for Diabetes / Research / Research Participation Opportunities
Share:

Research Participation Opportunities

Currently Recruiting

Learn more about our research studies and the criteria for participating.

This study aims to compare effect of the investigational medication called empagliflozin used together with the single-hormone artificial pancreas (Dexcom G6, t-slim pump, Android phone) and with conventional insulin pump therapy. In total 28 patients with type 1 diabetes will be enrolled across 2 research sites (Toronto & Montreal). Study includes four 28-days interventions, 7 office visits and one phone visit over approx. 5 month period.

Who can participate in this trial?

  • People with type 1 diabetes
  • Who use insulin pump
  • Who are willing to come for 7 visits to our office over 5 months period

Principal Investigator: Dr. Bruce Perkins

How can I take part or learn more about the study?

If you are interested in participation, please call Andrej Orszag at (416)-586-4800 ext. 7625.

To participate in any of these trials you need to be at least 18 years old and cannot be pregnant or breastfeeding. There are additional criteria for participation in the trial, which are not listed on this site.

This study aims to recruit individuals with duration of diabetes for more than 50 years. We will collect information about the medical history, diabetes management and lifestyle through a questionnaires used for similar studies in other countries. Comparison of data obtained from participants who are affected by complications to those who are not, will help us better understand protective factors and enables researchers to develop therapies and recommendations to prevent type 1 diabetes complications. Learn more about the study on the Diabetes Longevity website.

Who can participate in this trial?

  • People with type 1 diabetes diagnosed more than 50 years ago
  • Who are willing to fill in questionnaire at home (up to 1.5 hour of time)

Principal Investigator: Dr. Bruce Perkins

How can I take part or learn more about the study?

If you are interested in participation, please call Andrej Orszag at (416)-586-4800 ext. 7625.

To participate in any of these trials you need to be at least 18 years old and cannot be pregnant or breastfeeding. There are additional criteria for participation in the trial, which are not listed on this site.

This study will include 22 participants who were diagnosed with type 1 diabetes less than 3 months ago. We will study effect of experimental drug ustekinumab and compare it to placebo over the 1.5 year period. Ustekinumab is given in infusion or injections and participants will need to attend 11 study visits. We expect, that ustekinumab will protect pancreas cells and may delay, or temporarily stop, progress of diabetes.

Who can participate in this trial?

  • People who were diagnosed with type 1 diabetes in the past 3 months
  • Between 18-25 years old
  • Who are willing to come for 11 visits over 1.5 years (some of them up to 4hours long)

Principal Investigator: Dr. Bruce Perkins

How can I take part or learn more about the study?

If you are interested in participation, please call Andrej Orszag at (416)-586-4800 ext. 7625.

To participate in any of these trials you need to be at least 18 years old and cannot be pregnant or breastfeeding. There are additional criteria for participation in the trial, which are not listed on this site.

Study description: Women who have had gestational diabetes have an increased risk of developing Type 2 diabetes in the years after their pregnancy. This is due to the progressive worsening over time of the pancreatic beta-cells, which product insulin for the body. The EMPA study investigates whether a new diabetes medication, as compared to a placebo, is able to preserve beta-cell function and therefore possibly prevent Type 2 diabetes in women who have had gestational diabetes.

Study eligibility criteria:

  • Gestational diabetes in pregnancy within the past 3 years
  • 20 to 50 years old
  • Not currently pregnant or breastfeeding
  • Willing to come in for 4 study visits over 12 months

Principal Investigator: Dr. Caroline Kramer

How can I take part or learn more about the study?

If you are interested in finding out more about participating in this study, please call Alexandra Emery at 416-586-8778 or send an email to [email protected].

Type 2 Diabetes Mellitus (T2DM) is a chronic progressive condition that is characterized by worsening glycemic control over time. This process is driven by deterioration of the pancreatic beta-cells that make insulin. Early in the course of diabetes, short-term treatment with insulin can reverse this deterioration of the beta-cells and induce a remission of T2DM. With the PREVAIL study, we are conducting a Canadian Institutes of Health Research (CIHR) funded trial comparing three approaches to inducing remission in patients with early T2DM.

Who can participate in this trial?

  • People on 0-2 oral anti-diabetic medications
  • Who are within 7 years of diabetes diagnosis
  • With a recent A1C level between 5.5 and 9.0%
  • Are willing to come for 4 study visits over 20 weeks

Principal Investigators: Dr. Ravi Retnakaran and Dr. Bernard Zinman.

How can I take part or learn more about the study?

If you are interested in receiving more information regarding the PREVAIL trial, please call Alex Emery at (416) 586-8778 or email [email protected].  

One known cause of type 2 diabetes is beta-cell dysfunction, where the pancreas cannot produce enough insulin for the body’s need. Unfortunately, no anti-diabetic medication has been shown to prevent the worsening of beta-cell function over time. Intermittent fasting, however, has been shown to promote weight loss and improve cardio-metabolic function, and thus the Leadership Sinai Centre for Diabetes is conducting research to investigate whether intermittent fasting can improve pancreatic beta-cell function as compared to a standard lifestyle recommendation.

Time Commitment: You will be in this study for a total of 20 weeks. There will be 5 visits during the study and each will last 2.5 hours.

Who can participate in this trial?

  • Received a T2DM diagnosis within the last 10 years
  • Age: 20 – 70 years
  • Hemoglobin A1c: 5.5 - 9.0
  • BMI: ≥ 25 kg/m²
  • TD2M treatment:
  • Lifestyle only
  • Metformin
  • DPP-4 Inhibitor

Principal Investigator: Dr. Caroline Kramer

How can I take part or learn more about the study?

If you have interest in finding out more about participating in this study please call Shamini Murugavel 416-586-4800 ext. 3802 or send an email to [email protected]

This is a study to determine the effectiveness of a closed-loop insulin delivery system (670G) used during the early postpartum period compared to standard of care pump therapy with continuous glucose monitoring.

Who can participate in this trial?

  • Pregnant women with Type 1 Diabetes

Principle Investigator: Dr. Denice Feig

How can I take part or learn more about the study?

If you have interest in finding out more about participating in this study please call (416) 586-8590.

This is a study to determine the effectiveness of using a closed-loop insulin delivery system (Tandem Control IQ) during pregnancy compared to standard of care with continuous glucose monitoring.

Who can participate in this trial?

  • Pregnant women with Type 1 Diabetes

Principle Investigator: Dr. Denice Feig

How can I take part or learn more about the study?

If you have interest in finding out more about participating in this study please call (416) 586-8590.  

Ongoing Research (not actively recruiting)

Leading research at the Leadership Sinai Centre for Diabetes.

MiTy Kids: This is a follow-up study of the children of the mothers in the MiTy trial. We are looking to see if the children's growth and development is different if their mother was given metformin during pregnancy.  MiTy Kids is looking at children up to age 2 years. 

The MiTy Tykes study will be starting shortly and looking at the same children aged 5-8 years of age.

Principal Investigator: Dr. Denice Feig

CONCEPTT Kids: This is a follow-up study of the children of the mothers in the CONCEPTT study. We are looking to understand the neurodevelopment of children of mothers with type 1 diabetes.

Principal Investigator: Dr. Denice Feig

Type 2 diabetes is a progressive disease. In people with type 2 diabetes, the ability of the body to make its own insulin tends to deteriorate over time. The medications currently used to treat diabetes do not stop this process, and as a result, blood sugar levels tend to increase over time. Previous studies suggest that taking injections of insulin for a few weeks may be able to protect the beta-cells in the body that produce insulin. This effect on beta cells has allowed people with type 2 diabetes to then temporarily maintain blood sugar levels for several months afterwards, without any diabetes medication. However, this "remission" phase is ultimately temporary and wanes over time. The RESET IT study is a clinical trial that focuses on trying to maintain this remission, thus potentially modifying the natural history of type 2 diabetes.

Results will be published shortly, and will be made available on this website.

Principal Investigators: Dr. Ravi Retnakaran and Dr. Bernard Zinman.

If you are interested in participating in similar studies to RESET IT, please call Alex Emery at (416) 586-8778 or email [email protected]

In this study, we are studying changes in the body that may contribute to the development of type 2 diabetes in women in the years after pregnancy. Participating women are recruited in pregnancy and then undergo assessment at 3-months and 1-year after delivery. At the latter visit, they are offered the opportunity to participate in the long-term cohort study in which they undergo assessment every 2 years thereafter.

This study has demonstrated that maternal glucose tolerance in pregnancy can provide a window into a woman's future risk of type 2 diabetes and cardiovascular disease. This insight provides the opportunity for improved surveillance and early detection of the changes that contribute to this risk. Furthermore, this recognition raises the possibility of early intervention to modify this risk and thereby ideally prevent the development of diabetes and cardiovascular disease.

This study has yielded over 50 scientific publications.

Principal Investigators: Dr. Ravi Retnakaran, Dr. Bernard Zinman (co), Dr. Tony Hanley (co)

External Research

Helping to improve the lives of those living with diabetes across Canada.

Connect1d is a digital registry that aims to improve awareness, accessibility and recruitment into clinical trials. The platform collects data directly from patients to create a national T1D registry. Using Connect1d, patients can easily access innovative treatments and have the opportunity to work with the community to drive priorities in research, policy and clinical care.

Note: Connect1d is not directly associated with Sinai Health or Leadership Sinai Centre for Diabetes and has their own Privacy Policy and Terms of Use.

Frequently Asked Questions

Answers to your frequently asked questions about participating in clinical research.